Buy & Sell UiPath Inc (PATH) – UiPath Inc Price Today
Aura AI Summary
Key Stats
- $5.82BMarket Cap
- TechnologySector
- -24.66%3M Drawdown
- $4.60BEnterprise Value
- -Dividend Yield
- 14% Buy | 86% SellTrading Activity
- 132 daysTypical Hold Time
UiPath Inc (PATH) is currently valued at a market capitalization of $5.82B, with an enterprise value of $4.60B. Over the past 52 weeks, UiPath Inc has traded between a low of $9.38 and a high of $19.29, highlighting its annual price range. Over the past three months, UiPath Inc has recorded a drawdown of -24.66%, reflecting recent price volatility. On average, investors hold UiPath Inc for approximately 132 days, indicating typical investor behavior on the platform.
About UiPath Inc
UiPath Inc creates an end-to-end platform that provides automation with user emulation at its core. Its platform is built to be used by employees throughout a company and to address a wide variety of use cases, from simple tasks to long-running, complex business processes. It generates revenue from the sale of licenses for its proprietary software, maintenance and support, and professional services. It generates a majority of the revenues from the US, followed by Romania and the rest of the world.
Most Recent News
AI boom drives strong earnings beats, policy debates, and major tech moves worldwide
Recent financial reports show strong earnings beats driven by surging demand for artificial intelligence (AI) technologies, with companies like ServiceTitan, Palo Alto Networks, and CrowdStrike exceeding revenue and earnings estimates. Policymakers i...

VanEck marks 20 years of GDX ETF, highlighting its impact on the ETF industry and gold investing.
VanEck celebrates 20 years of its GDX ETF, reflecting on how it transformed the ETF industry and the long-term investment case for gold. The discussion features insights from VanEck CEO Jan van Eck and COO Adam Phillips on the ETF's origin and future...

Healthcare stocks shift from defensive to value plays amid tech-driven market growth.
Healthcare stocks, long underperforming compared to tech, are now seen as value opportunities for investors heavily invested in growth sectors like AI. Mizuho strategist Jared Holz highlights Merck as a prime example, with its strong Keytruda franchi...
